These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29934218)

  • 1. Design, synthesis, in vitro and in vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism studies.
    Lei M; Feng H; Bai E; Zhou H; Wang J; Shi J; Wang X; Hu S; Liu Z; Zhu Y
    Bioorg Med Chem; 2018 Aug; 26(14):3975-3981. PubMed ID: 29934218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
    Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y
    Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
    Zhang W; Wang X; Zhang H; Wen T; Yang L; Miao H; Wang J; Liu H; Yang X; Lei M; Zhu Y
    Bioorg Med Chem; 2021 Jun; 40():116182. PubMed ID: 33971487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and discovery of novel dipeptide boronic acid ester proteasome inhibitors, an oral slowly-released prodrug for the treatment of multiple myeloma.
    Wang X; Zhang W; Wen T; Miao H; Hu W; Liu H; Lei M; Zhu Y
    Eur J Med Chem; 2023 Mar; 250():115187. PubMed ID: 36806958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
    Ge Y; Li A; Wu J; Feng H; Wang L; Liu H; Xu Y; Xu Q; Zhao L; Li Y
    Eur J Med Chem; 2017 Mar; 128():180-191. PubMed ID: 28182990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
    Shi J; Lei M; Wu W; Feng H; Wang J; Chen S; Zhu Y; Hu S; Liu Z; Jiang C
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1958-62. PubMed ID: 26965867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D-QSAR-aided design, synthesis, in vitro and in vivo evaluation of dipeptidyl boronic acid proteasome inhibitors and mechanism studies.
    Lei M; Feng H; Wang C; Li H; Shi J; Wang J; Liu Z; Chen S; Hu S; Zhu Y
    Bioorg Med Chem; 2016 Jun; 24(11):2576-2588. PubMed ID: 27117691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
    Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
    Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of curcumin derivatives modified with α-amino boronic acid as proteasome inhibitors.
    Zhang W; Bai H; Han L; Zhang H; Xu B; Cui J; Wang X; Ge Z; Li R
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2459-2464. PubMed ID: 29886021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome.
    Sun Q; Zhou T; Xi D; Li X; Lü Z; Xu F; Wang C; Niu Y; Xu P
    Eur J Med Chem; 2020 Apr; 192():112160. PubMed ID: 32146375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.
    Yu J; Xu L; Hong D; Zhang X; Liu J; Li D; Li J; Zhou Y; Liu T
    Eur J Med Chem; 2019 Jan; 161():543-558. PubMed ID: 30391816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effects of tyropeptin-boronic acid derivatives: New proteasome inhibitors.
    Momose I; Abe H; Watanabe T; Ohba S; Yamazaki K; Dan S; Yamori T; Masuda T; Nomoto A
    Cancer Sci; 2014 Dec; 105(12):1609-15. PubMed ID: 25251038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
    Zhang J; Shen L; Wang J; Luo P; Hu Y
    Med Chem; 2014; 10(1):38-45. PubMed ID: 23676009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of peptidyl epoxyketone proteasome inhibitors composed of β-amino acids.
    Zhang J; Han M; Ma X; Xu L; Cao J; Zhou Y; Li J; Liu T; Hu Y
    Chem Biol Drug Des; 2014 Nov; 84(5):497-504. PubMed ID: 24751157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis, and Biological Activity of Isosyringolin A.
    Kitahata S; Chiba T; Yoshida T; Ri M; Iida S; Matsuda A; Ichikawa S
    Org Lett; 2016 May; 18(9):2312-5. PubMed ID: 27123978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, in vitro and in vivo biological evaluation, and comprehensive understanding of structure-activity relationships of dipeptidyl boronic acid proteasome inhibitors constructed from β-amino acids.
    Zhu Y; Wu G; Zhu X; Ma Y; Zhao X; Li Y; Yuan Y; Yang J; Yu S; Shao F; Lei M
    J Med Chem; 2010 Dec; 53(24):8619-26. PubMed ID: 21077681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
    Niroula D; Hallada LP; Le Chapelain C; Ganegamage SK; Dotson D; Rogelj S; Groll M; Tello-Aburto R
    Eur J Med Chem; 2018 Sep; 157():962-977. PubMed ID: 30165344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
    Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
    ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
    Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y
    Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urea-containing peptide boronic acids as potent proteasome inhibitors.
    Han LQ; Yuan X; Wu XY; Li RD; Xu B; Cheng Q; Liu ZM; Zhou TY; An HY; Wang X; Cheng TM; Ge ZM; Cui JR; Li RT
    Eur J Med Chem; 2017 Jan; 125():925-939. PubMed ID: 27769033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.